The content on this site is intended for healthcare professionals only
Dr Arvind Dasari speaks to ecancer about the clinical utility of including circulating tumour DNA (ctDNA) monitoring in standard of care colorectal cancer surveillance.
Dr Dasari explores new findings showing how circulating tumour DNA (ctDNA) testing can transform colorectal cancer follow-up after surgery. He says that detecting oligometastatic disease (OMD) is key to offering curative metastasis-directed therapy (MDT).
The results form this trial show that ctDNA testing detects recurrence and treatable metastases far better than standard methods. ctDNA-positive patients are much more likely to receive potentially curative MDT.
Dr Dasari highlights that future CRC follow-up should consider personalised surveillance based on ctDNA results.
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety
ASCO 2026: Latest updates in mRCC
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Revolutionising myeloma treatment through immune profiling
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
